NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Engimmune Therapeutics

Engimmune Therapeutics

Private
AllschwilHealthcare & Life Scienceshttps://www.engimmune.com/

Last Round

Seed

May 3, 2022

Total Funding Raised

$16.7M

Company Overview

Engimmune Therapeutics is a biotechnology company that develops targeted, 'off-the-shelf' soluble T-cell receptor (TCR) drugs to treat solid tumour cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

TCR therapiessoluble TCRoff-the-shelf cell therapyAI drug discoveryimmunotherapysolid tumor therapiesTCR engineeringprotein engineeringdrug discovery platformAI biotechgenerative biologygenome editingautoimmune disease therapieshigh-throughput screening

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Engimmune Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Engimmune Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Engimmune Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 3, 2022
View all Funding Rounds

Key People

Founding team and executive leadership

Lars Nieba

CEO

Executive Team

Engimmune Therapeutics Investors

Notable investors and investment history

Engimmune Therapeutics investors
InvestorRounds
Novo HoldingsSeed
Pureos BioventuresSeed
BaseLaunchSeed
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 16, 2023

    Grew 19% QoQ, from 21 to 25 employees.

  • May 3, 2022

    $17M round led by Novo Holdings and Pureos Bioventures.

View all signals

Engimmune Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Engimmune Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Engimmune Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersAllschwil
Employee Range15
Year Founded2021
Last FundingMay 3, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.